Clinical trial · Interventional
Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation
Determination of the Predictive Value of FDG-PET-CT Scans, Blood Proteins and Blood Cells for the Prognosis for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation
NCT00522639CI-TRIAL-00002414FDG-PET lungterminatedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor accrual
Summary
Brief summary (as posted)
The objective of the study is to investigate the evolution ofn 18F-deoxyglucose (FDG) uptake and the tumour characteristics determined in the plasma of patients with lung cancer of during and after concurrent radiotherapy and chemotherapy
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| SCLC | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-deoxyglucose (FDG) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Tumour response, measured with FDG-PET-CT scans 3 months post-radiation. as a function of delta FDG uptake the first week during radiotherapy
- timeFrame
- 9 months post-radiation
Secondary outcomes (1)
- measure
- - Incidence of acute radiation-induced oesophagitis - Incidence of radiation-induced pulmonary toxicity 3 and 9 months post-radiation
- timeFrame
- 9 months post-radiation
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological proven non-small cell or small cell lung cancer UICC stage I-III (in case of small cell lung cancer: limited stage) * WHO performance status 0-2 * Less than 10 % weight loss the last 6 months * In case of previous chemotherapy, concurrent chemo-radiotherapy can start after a minimum of 21 days after the last chemotherapy course * No recent (\< 3 months) severe cardiac disease (arrhythmia, congestive heart failure, infarction) * No active peptic oesophagitis * Life expectancy more than 6 months * Measurable cancer * Willing and able to comply with the study prescriptions * 18 years or older * Not pregnant and willing to take adequate contraceptive measures during the study * Have given written informed consent before patient registration * No previous radiotherapy to the chest Exclusion Criteria: * Not non-small cell or small cell histology, e.g. mesothelioma, lymphoma * Malignant pleural or pericardial effusion * History of prior chest radiotherapy * Recent (\< 3 months) myocardial infarction * Uncontrolled infectious disease * Distant metastases (stage IV) * Patients with active peptic oesophagitis in the last year * Less than 18 years old * Pregnant or not willing to take adequate contraceptive measures during the study
References
Publications (0)
Data not yet available
No reference posted for this study.